Characteristics of female community members participating in IDIs (N = 21).

<p>Characteristics of female community members participating in IDIs (N = 21).</p

Cascade of PMTCT services by clinic location.

<p>Cascade of PMTCT services by clinic location.</p

Conceptual framework for the analysis of patient-provider interactions in Tanzania.

<p>Conceptual framework for the analysis of patient-provider interactions in Tanzania.</p

Key elements of patient-centred care conceived by Mead and Bower.

<p>Key elements of patient-centred care conceived by Mead and Bower.</p

Characteristics of PLA group participants (3 male groups and 3 female groups each with 8–12 participants, N = 61 participants in total).

<p>Characteristics of PLA group participants (3 male groups and 3 female groups each with 8–12 participants, N = 61 participants in total).</p

Crude and adjusted odds ratios for clinical and behavioural factors associated with VCT uptake at Sero-6.

*<p>p≤0.05,</p>¶<p>p≤0.1.</p><p>Adjusted for all socio-demographic, clinical & behavioural factors associated with VCT use in univariable analyses (p≤0.10) and remaining significant in multivariable analyses.</p><p>α Reported or documented (at an earlier sero-survey round) previous HCT use.</p><p>Δ Spouse’s HIV status & VCT use at current sero-survey round.</p><p>Ω Frequency of condom use in last 12 months considering three most recent partners.</p

Characteristics of individuals attending both Sero-5 and Sero-6 and factors associated with repeat use of VCT at each round^#.

<p>#Characteristics and behavioural variables are those reported at Sero-6, unless otherwise stated.</p>*<p>p≤0.05,</p>¶<p>p≤0.1.</p><p>Δ Spouse HIV status and VCT use at Sero-6.</p><p>Ω Frequency of condom use in last 12 months considering three most recent partners.</p

Univariable analysis of factors most strongly associated with VCT uptake at sero-surveys 4, 5 and 6^¤.

¤<p>Figures for VCT uptake at Seros 4 and 5 reflect an update on previous figures presented by Wringe <i>et al</i><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062212#pone.0062212-Wringe1" target="_blank">[13]</a> and Isingo <i>et al</i><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062212#pone.0062212-Isingo1" target="_blank">[14]</a>. The figures are provided here for context.</p>*<p>p≤0.05,</p>¶<p>p≤0.1.</p><p>α Reported or documented (at an earlier sero-survey round) previous HCT use.</p><p>Δ Spouse’s HIV status & VCT use at current sero-survey round.</p

By HIV status: number of times individuals reported using VCT at an earlier sero-survey round, versus number of times VCT was actually used at the earlier round.

<p>By HIV status: number of times individuals reported using VCT at an earlier sero-survey round, versus number of times VCT was actually used at the earlier round.</p

Among those who attended Sero 6, proportions of men (n = 3,131) and women (n = 4,877) using different HCT services.

<p>Among those who attended Sero 6, proportions of men (n = 3,131) and women (n = 4,877) using different HCT services.</p